ResearcherOchsner Medical CenterActive in the last 2 years

Passant Shaker

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9750-9310; OpenAlex author ID A5079132757. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2026: 1 paper

Papers 1

Second-Line Systemic Therapy Following First-Line FOLFIRINOX or NALIRIFOX in Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. Co-author DOI 10.1007/s12029-026-01601-z ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jonathan D. Mizrahi · 1 shared paper, 2026 · strength 0.36
- Paper Second-Line Systemic Therapy Following First-Line FOLFIRINOX or NALIRIFOX in Metastatic Pancreatic Ductal Adenocarcinom… DOI 10.1007/s12029-026-01601-z ↗
Jane Elizabeth Rogers · 1 shared paper, 2026 · strength 0.36
- Paper Second-Line Systemic Therapy Following First-Line FOLFIRINOX or NALIRIFOX in Metastatic Pancreatic Ductal Adenocarcinom… DOI 10.1007/s12029-026-01601-z ↗
Shubham Pant · 1 shared paper, 2026 · strength 0.36
- Paper Second-Line Systemic Therapy Following First-Line FOLFIRINOX or NALIRIFOX in Metastatic Pancreatic Ductal Adenocarcinom… DOI 10.1007/s12029-026-01601-z ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.